南方医科大学学报 ›› 2006, Vol. 26 ›› Issue (08): 1230-1232.

• • 上一篇    下一篇

90Y标记单克隆抗体CD45的研究

扶云碧; 李贵平; 孟凡义;   

  1. 南方医科大学南方医院血液科; 南方医科大学南方医院核医学科; 南方医科大学南方医院血液科 广东广州510515; 广东广州510515;
  • 出版日期:2006-08-20 发布日期:2006-08-20
  • 基金资助:
    广东省自然科学基金(20005300571);广州市科技计划项目(2005J1-C0141)~~

Labeling of CDTPA-dianhydride-coupled CD45 monoclonal antibody with yttrium-90

FU Yun-bi1, LI Gui-ping2, MENG Fan-Yi1 1Department of Hematology, 2Department of Nuclear Medicine, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China   

  1. 南方医科大学南方医院血液科; 南方医科大学南方医院核医学科; 南方医科大学南方医院血液科 广东广州510515; 广东广州510515;
  • Online:2006-08-20 Published:2006-08-20

摘要: 目的制备90Y标记的CD45单克隆抗体,为用90Y-CDTPA-CD45mAb治疗急性白血病奠定基础。方法利用环酐DTPA为络合剂,螯合90Y与CD45mAb,并对90Y-CDTPA-CD45mAb的标记率、放化纯度、稳定性、比活度、免疫活性进行检测。结果在CDTPA与IgG的最佳摩尔比为20∶1的条件下,90Y-CDTPA-CD45mAb的标记率为95%,放化纯度达99.8%,稳定性良好,比活度为1.9mCi/mg,免疫活性与未标记的CD45mAb相比无明显差异。结论90Y-CDTPA-CD45mAb是一个较理想的靶向治疗制剂,可以用于下一步的急性白血病治疗研究。 

Abstract: Objective To explore the methods for labeling CDTPA-coupled CD45 monoclonal antibody (mAb) with yttrium-90 (90Y) for potential acute myeloid therapy. Methods CD45 mAb was labeled with 90Y by CDTPA and the labeling rate, radiochemical purity, final specific activity, and immunological activity of the mAb were detected. Results With the optimal molar ratio of CDTPA/Ab at 20∶1, the labeling rate was 95%, radiochemical purity 99.8%, and final specific activity 1.9 mCi/mg. This conjugate was stable in vitro with comparable immunological activity in comparison with unlabeled CD45 mAb. Conclusion 90Y-CDTPA-CD45 mAb possesses good properties as an ideal targerting therapeutic agent for acute leukemia. 

中图分类号: